Incyte Corporation

NASDAQ:INCY

Biotechnology

Healthcare
$117.80 -0.78%

-$0.77 today

Market cap
$24.01B
Beta
0.79
P/E (TTM)
13.7
EPS (TTM)
$7.18
52W Low $66.74High $112.29

Volume 1.21M

Average 1.58M

INCY Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Incyte CorporationNASDAQ: INCY

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables growth accelerates

Q2 FY2026 accounts payables of $22.43M rose 12.7% year over year, ahead of the -48.5% change in trailing-twelve-month accounts payables. Sequentially, it fell 4.3% from the prior quarter. Over 3 fiscal years it compounded at -60.4% a year.

Context

  • Accounts payables amounted to 0.1% of revenue in FY2025, down 2.0 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +12.7% holds above the trailing-twelve-month pace of -48.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$22.43M-4.3% QoQ
Last fiscal yearDec 2025
$6.56M-92.6% YoY
LTMJun 2026
$34.69M-48.5% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.7%——
1 year-92.6%——
3-year CAGR-60.4%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
6.56M USD
Year-over-year change
-92.6%
4-year CAGR
-45.3%

Accounts Payables vs competitors

How INCY compares with its peers on the latest reported figures

  • INCY's LTM Jun 2026 accounts payables of $34.69M is the 3rd largest of the 11 companies compared; the peer median is $3.38M.
  • Its year-over-year change of -48.5% is the 7th highest of 10, against a peer median of +191.5%.
  • Accounts payables amounts to 0.6% of revenue for INCY, versus a peer median of 3.6%.
INCY Competitors Peer median
Accounts Payables for INCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$1.33B +216.1%—8.6%
GMABGenmab A/SLTM Jun 2026$37.17M —+12.3%0.9%
INCYIncyte CorporationLTM Jun 2026$34.69M -48.5%-60.4%0.6%
LEGNLegend Biotech CorporationLTM Sep 2026$26.31M -138.8%-15.0%1.9%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$25.05M +537.3%—3.6%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$14.4M +31.4%—5.0%
EXELExelixis, Inc.LTM Jul 2026$8.01M -69.6%—0.3%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$4.37M +2029.8%-8.6%—
VSTMVerastem, Inc.LTM Mar 2026$2.4M +1061.2%+48.0%4.8%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$892K +191.5%+18.1%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$199K -91.4%——
Peer median (excluding INCY) $3.38M+191.5%+12.3%3.6%

Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income948.58M340.66M597.6M32.62M1.29B
Depreciation & Amortization57.84M67.86M82.66M89.25M93.29M
Deferred Income Tax(465.6M)57.09M(158.9M)(85.55M)247.69M
Stock-Based Compensation183.01M188.42M215.89M266.06M249.35M
Change in Working Capital(14.57M)198.81M(248.65M)138.24M(527.16M)
Accounts Receivables(134.31M)(28.58M)(98.68M)(111.59M)(170.77M)
Inventory(20.97M)(67.5M)(170.15M)(127.63M)(58.51M)
Accounts Payables73.34M105.44M(167.95M)88.16M6.56M
Other Working Capital67.36M189.46M188.12M289.3M(304.44M)
Other Non-Cash Items40.23M117.11M7.89M(105.28M)63.69M
Operating Cash Flow749.49M969.94M496.49M335.34M1.41B
Capital Expenditures(181.01M)(77.83M)(32.49M)(86.26M)(58.87M)
Acquisitions (Net)00000
Purchases of Investments(268.68M)(79.86M)(466.02M)(258.37M)(303.38M)
Sales of Investments241.98M79.15M305.83M516.05M284.64M
Other Investing Activities00000
Investing Cash Flow(207.7M)(78.54M)(207.68M)157.52M(102.61M)
Debt Repayment(2.42M)(2.86M)(3.36M)(3.8M)(4.54M)
Common Stock Issued58.63M61.12M35.84M49.3M221.76M
Common Stock Repurchased000(2B)(19.1M)
Dividends Paid00000
Other Financing Activities(50.03M)(59.05M)(52.51M)(62.26M)(97.08M)
Financing Cash Flow6.18M(794K)(20.03M)(2.02B)101.04M
Effect of Forex Changes(3.53M)3.38M(6.82M)3.15M(1.94M)
Net Change in Cash544.43M893.98M261.95M(1.53B)1.41B
Free Cash Flow568.48M892.11M464M249.07M1.35B

Incyte Corporation

NASDAQ:INCY

Intrinsic Alpha fair value

Locked

Current Price

$117.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.